Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)
Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment optio...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
6 February 2019
|
| In: |
Journal of Clinical Medicine
Year: 2019, Jahrgang: 8, Heft: 2, Pages: 1-14 |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm8020200 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jcm8020200 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2077-0383/8/2/200 
|
| Verfasserangaben: | Susanne Hofmann, Maria-Luisa Schubert, Lei Wang, Bailin He, Brigitte Neuber, Peter Dreger, Carsten Mueller-Tidow and Michael Schmitt |
| Zusammenfassung: | Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients. |
|---|---|
| Beschreibung: | Gesehen am 26.11.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm8020200 |